 |
Previous Article | Next Article 
The Journal of Neuroscience, July 1, 1999, 19(13):5464-5472
Differential Regulation of Corticotropin-Releasing Hormone and
Vasopressin Gene Transcription in the Hypothalamus by
Norepinephrine
Keiichi
Itoi1, 2,
Dana L.
Helmreich1,
Manuel O.
Lopez-Figueroa1, and
Stanley J.
Watson1
1 Mental Health Research Institute, University of
Michigan, Ann Arbor, Michigan 48109, and 2 The Second
Department of Internal Medicine, Tohoku University School of Medicine,
Sendai 980-8574, Japan
 |
ABSTRACT |
All stress-related inputs are conveyed to the hypothalamus via
several brain areas and integrated in the parvocellular division of the
paraventricular nucleus (PVN) where corticotropin-releasing hormone
(CRH) is synthesized. Arginine vasopressin (AVP) is present in both
magnocellular and parvocellular divisions of the PVN, and the latter
population of AVP is colocalized with CRH. CRH and AVP are co-secreted
in the face of certain stressful stimuli, and synthesis of both
peptides is suppressed by glucocorticoid. CRH and AVP stimulate
corticotropin (ACTH) secretion synergistically, but the physiological
relevance of the dual corticotroph regulation is not understood.
Norepinephrine (NE) is a well known neurotransmitter that regulates CRH
neurons in the PVN. We explored the mode of action of NE on CRH and AVP
gene transcription in the PVN to examine the effect of the
neurotransmitter on multiple genes that are responsible for a common
physiological function. After NE injection into the PVN of conscious
rats, CRH heteronuclear (hn) RNA increased rapidly and markedly in the
parvocellular division of the PVN. AVP hnRNA did not change
significantly in either the parvocellular or magnocellular division of
the PVN after NE injection. The present results show that the
transcription of CRH and AVP genes is differentially regulated by NE,
indicating the complexity of neurotransmitter regulation of multiple
releasing hormone genes in a discrete hypothalamic neuronal population.
Key words:
rat; paraventricular nucleus; parvocellular division; magnocellular division; catecholamines; messenger RNA; in
situ hybridization; corticotropin
 |
INTRODUCTION |
The medial parvocellular division of
the paraventricular nucleus (PVN) is the major source of the
tuberoinfundibular corticotropin-releasing hormone (CRH) neurons (Bloom
et al., 1982 ; Merchenthaler et al., 1982 ; Olschowka et al., 1982 ),
which play a pivotal role in the regulation of ACTH secretion (Vale et
al., 1981 ) and synthesis (Bruhn et al., 1984 ) in the anterior
pituitary. Arginine vasopressin (AVP), colocalized in a proportion of
CRH neurons in the parvocellular division of the PVN (Tramu et al.,
1983 ), is incorporated into the secretory granule along with CRH
(Whitnall et al., 1985 ) and co-secreted into the portal circulation in
response to particular classes of stressful stimuli (Plotsky, 1987a ).
CRH and AVP act synergistically on ACTH secretion in the anterior
pituitary (Gillies et al., 1982 ). Synthesis of these two peptides in
the parvocellular division of the PVN is suppressed by glucocorticoids
in a parallel manner (Itoi et al., 1987 ). On the basis of these
findings, both CRH and AVP have been generally accepted as endogenous
ACTH secretagogues, although the physiological implication of the dual
regulation of the corticotroph has not yet been fully understood.
The posterior magnocellular division is the major source of AVP neurons
in the PVN whose axons terminate in the posterior pituitary together
with another population of AVP axons originating from the supraoptic
nuclei (SON) (Dierickx, 1980 ). AVP, secreted from the posterior
pituitary into the systemic circulation, regulates water and
electrolyte homeostasis (Skorecki et al., 1992 ) and possibly
cardiovascular function (Robertson, 1977 ).
The distinct roles of the parvocellular and magnocellular
neurosecretory neurons are clear, but both of these populations of
neurons in the PVN receive noradrenergic inputs from the lower brainstem (Sawchenko and Swanson, 1981 ). Although the medial
parvocellular division is mainly innervated by the A2 cell
group, the posterior magnocellular division (as well as the SON) is
mainly innervated by the A1 cell group (Cunningham and
Sawchenko, 1988 ).
These ascending noradrenergic pathways are implicated, among other
neural pathways, in conveying stress-related inputs to the PVN
(Liposits et al., 1986 ; Plotsky et al., 1989 ; Itoi et al., 1998 ).
Norepinephrine (NE) has been shown to stimulate CRH neurons (Itoi et
al., 1998 ), and it was demonstrated recently that NE stimulated CRH
mRNA expression in vivo (Itoi et al., 1994 ). The role of NE
in regulating the release of AVP has been the subject of much
controversy (Renaud and Bourque, 1991 ), and the effect of NE on AVP
gene expression has not been reported.
The aim of the present study was to examine the effect of NE on CRH and
AVP gene transcription in the PVN and to understand the physiological
roles of the ascending noradrenergic pathway in maintaining mammalian
endocrine homeostasis. To attain this aim the following experimental
protocols were chosen. First, NE was microinjected directly into the
PVN of conscious rats. Second, we used riboprobes that were
complementary to the CRH and AVP intronic sequences to examine the
levels of primary transcripts. Third, semiquantitative in
situ hybridization was used to explore the effect of NE on AVP
gene regulation in the parvocellular and magnocellular divisions separately.
 |
MATERIALS AND METHODS |
Acute NE microinjection. Under pentobarbital
anesthesia (50 mg/kg, i.p.), stainless steel guide cannulas were
stereotaxically implanted unilaterally (on the left side) 2 mm above
the dorsolateral border of the rat PVN and left in place as described
previously (Itoi et al., 1994 , 1996 ). Unilateral microinjection
protocol was used in this study assuming that the contralateral side
could serve as control. The coordinates used for the PVN were 1.6, 0.8, and 8.0 mm posterior to the Bregma, lateral to the midline, and vertical from the skull surface, respectively. A stainless steel stylet
was placed in the guide cannula to prevent its obstruction by clots.
After the guide cannulas were implanted, rats were housed in individual
cages. Rats were handled daily for 1 week before experiments to get
them accustomed to the experimental conditions and to minimize the
stress they might be subjected to during experiments. The stylet was
withdrawn 24 hr before the experiment.
Experiments were performed on conscious rats between 8 A.M. and
11 A.M., before the circadian increase in plasma ACTH. Microinjection of norepinephrine bitartrate (Sigma, St. Lewis, MO) or vehicle was
performed as described previously (Itoi et al., 1994 ). A 31 gauge
needle connected to a 10 µl Hamilton syringe was inserted into the
guide cannula, so that the tip of the needle extended beyond the guide
cannula by 2 mm and reached the dorsolateral border of the PVN.
Artificial CSF at the following concentrations was used as
vehicle (Itoi et al., 1994 ) (in mM): NaCl 140, KCl 3.35, MgCl2 1.15, CaCl2 1.26, Na2HPO4 1.2, and
NaH2PO4 0.3, pH 7.4.
NE at a dose of 50 nmol dissolved in 0.1 µl of vehicle was injected
into the PVN over 10 sec. A 30 sec period was allowed for diffusion,
then the needle was withdrawn, and the animal was returned to the home cage.
Rats were decapitated 15, 30, 60, 90, and 120 min after injection.
Brains were rapidly removed and frozen in isopentane cooled to 40°C
on dry ice and stored at 80° C until they were processed. Trunk
blood was collected for determination of plasma ACTH levels.
To verify the extent of diffusion of injected NE,
[3H]-NE (0.1 µCi) and cold NE bitartrate were
added to make up 50 nmol/0.1 µl solution, which was injected into the
PVN of pentobarbital-anesthetized rats in the same manner as in the
experiment using conscious rats. Brains were removed, frozen, and
sectioned using a Leica cryostat. Frozen 20 µm sections were taken
every 100 µm from the rostral through the caudal regions over the
entire hypothalamus. All sections were thaw-mounted onto
poly-L-lysine (Sigma)-coated slides, air-dried, and exposed
to Amersham Hyperfilm for 1 week. Sections were stained by cresyl
violet to identify the anatomical location. The autoradiographs were
placed on the cresyl violet-stained sections and captured by a CCD
camera (TM-745, Pulnix). As shown in Figure
1, NE diffused to relatively large areas
around the PVN, but injected [3H]-NE was well
confined to the unilateral side. No diffusion into the ventricular
system was observed. Rostral or caudal extent of diffusion was <1
mm.

View larger version (128K):
[in this window]
[in a new window]
|
Figure 1.
The extent of diffusion of NE injected into the
PVN. [3H]-NE was added to cold NE to make up 50 nmol/0.1 µl and injected into the PVN of a pentobarbital-anesthetized
rat. Frozen sections were exposed to Amersham Hyperfilm. The sections
were also stained with cresyl violet. NE diffused to relatively large
areas including the PVN, but no diffusion was observed on the
contralateral side or in the cerebroventricular spaces. Scale bar, 2.0 mm.
|
|
In situ hybridization histochemistry. Frozen rat brains
were sectioned on a Bright-Hacker cryostat. Fourteen series of seven 10 µm sections were taken through the region of the hypothalamic PVN.
All sections were thaw-mounted onto poly-L-lysine-coated slides and stored at 80°C until they were processed. Sections were
removed from the freezer, fixed for 1 hr in 4% paraformaldehyde, rinsed three times in 2× SSC (1× SSC = 0.15 M NaCl,
0.015 M Na citrate, pH 7.0), and deproteinated with 0.2 µg/ml proteinase K (Boehringer Mannheim, Mannheim, Germany) for 10 min at 37°C. After deproteination, slides were washed for 1 min in
distilled water, placed in a solution containing acetic anhydride
(0.25%) in triethanolamine (0.1 M, pH 8) for 10 min at
room temperature, rinsed in distilled water, and then dehydrated
through graded ethanol solutions (50, 75, 85, 95, and 100%).
Antisense 35S-labeled cRNA probes for CRHin
[530 base pairs (bp) PvuII fragment, subcloned in pGem 3, complementary to sequences residing within CRH intron],
CRHex (680 bp BamHI fragment, subcloned in pGem
3, complementary to sequences residing within CRH exon 2), and
AVPin (735 bp PvuII fragment, subcloned in pGem
3, complementary to sequences residing within AVP intron 1) were
produced using either the T7 (for CRHin,
CRHex) or SP6 (for AVPin)
transcription system.
Plasmids containing subcloned cDNA or intron fragments were linearized
with appropriate restriction enzymes. Two types of labeling reaction
were used: (1) double-labeling conditions (for CRHin, CRHex), 1 µg linearized
plasmid, 5× T7 transcription buffer, 240 µCi
[ -35S]UTP (>1000 Ci/mmol dried; Amersham, Arlington
Heights, IL), 240 µCi [ -35S]CTP (>1000 Ci/mmol
dried), 150 µM ATP, 150 µM GTP, 12.5 mM dithiothreitol (DTT), 3.0 U/µl RNase inhibitor
(Promega, Madison, WI), and 0.5 U/µl T7 RNA polymerase (Promega); and
(2) single-labeling conditions (for AVPin), 1 µg
linearized plasmid, 5× SP6 transcription buffer, 250 µCi
[ -35S]UTP (>1000 Ci/mmol dried;), 150 µM ATP, 150 µM CTP, 150 µM
GTP, 12.5 mM DTT, 3.0 U/µl RNase inhibitor, and 0.5 U/µl SP6 RNA polymerase (Promega). The reaction was incubated for 2 hr at 37°C, and the labeled probe was separated from free nucleotide
over a Sephadex G50/50 column equilibrated in 0.1 M
Tris-HCl, pH 7.5, 12.5 mM EDTA, 0.15 M NaCl,
0.2% SDS, and 10 mM DTT.
35S-labeled cRNAs were diluted in hybridization buffer
(75% formamide, 10% dextran sulfate, 3× SSC, 50 mM
phosphate buffer, pH 7.4, 1× Denhardt's solution, 0.1 mg/ml yeast
tRNA) to yield 1,000,000 dpm/30 µl. Aliquots of 30 µl were
applied to each section, and the sections were coverslipped. Slides
were incubated overnight at 55°C in sealed plastic boxes moistened
with 50% formamide solution. After hybridization, coverslips were
removed, and the slides were rinsed twice in 2× SSC for 5 min each.
The tissue was treated with RNase A (200 µg/ml in Tris buffer
containing 0.5 M NaCl, pH 8.0) at 37°C for 30 min to
degrade any remaining single-stranded cRNA. Sections were washed
successively in 2×, 1×, 0.5×, and 0.1× SSC for 5 min each, followed
by a 60 min wash in 0.1× SSC at 70°C. Sections were dehydrated
through alcohols and exposed to Kodak XAR x-ray film (Eastman Kodak,
Rochester, NY). The exposure time was 24 hr for
CRHex, 5 d for CRHin, and
1.5 hr for AVPin. For quantitation of AVPin in
the parvocellular division of the PVN, sections were emulsion-dipped in
Kodak NTB2 nuclear emulsion for 8 d.
Semiquantitative analysis of in situ hybridization
autoradiographs. Semiquantitative analysis of in situ
hybridization autoradiographs was performed using Macintosh-based NIH
Image software. The x-ray film images were captured by a CCD camera
(TM-745, Pulnix) and subjected to densitometric analysis, yielding
measures of integrated optical density (area of the PVN × average
optical density). To compare the right versus left PVN, signal
intensity on each side of the PVN was quantitated separately from 10 sections (taken every 70 µm) per animal.
Dark-field images of emulsion-dipped sections hybridized with
AVPin probe were captured by a digital camera (Zeiss,
ProgRes 3012) mounted on a Zeiss microscope (Axioplan 2). To quantitate AVP hnRNA levels in the parvocellular division, areas expressing CRH
mRNA in the adjacent section were delineated, and the contours of those
areas were overlaid on the digitized image of AVP hnRNA using MCID
software (Imaging Research Inc.) (Fig.
2). Optical density of AVP hnRNA in this
area was quantitated on the NE-injected side and the contralateral side
separately from three sections per animal.

View larger version (50K):
[in this window]
[in a new window]
|
Figure 2.
Quantitative analysis of AVP hnRNA in the
parvocellular division of the PVN. In situ hybridization
was performed using a riboprobe corresponding to CRH exon 2, and the
contour of the CRH mRNA-positive area (indicated by the red
line) was overlaid on the digitized image of AVP hnRNA obtained
from the adjacent section, thus quantitating AVP hnRNA specifically in
the parvocellular division.
|
|
Hormone assay. Trunk blood was collected in a siliconized
glass tube with EDTA. Plasma was separated by centrifugation at 4°C
and placed in plastic tubes and frozen immediately. Immediately before
setting up the assay, frozen samples were thawed and centrifuged to
remove any fibrin clots. Plasma ACTH levels were determined by an
immunoradiometric assay kit (Nichols Institute). The sensitivity of the
assay was 1 pg/ml. Intra-assay and interassay coefficients of variation
were 3.2 and 6.8%, respectively. Plasma AVP levels were determined by
an RIA kit (Advanced ChemTech). The sensitivity of the assay was 1.5 pg/tube. Intra-assay and interassay coefficients of variation were 5 and 10%, respectively.
Experimental animals. Male Wistar rats purchased from
Charles Rivers (Wilmington, MA), weighing 270-325 gm, were used. Rats were allowed free access to food and water and maintained on a 12 hr
light/dark cycle (lights on, 7 A.M.-7 P.M.).
All animals used in these studies were treated in accordance with the
National Institutes of Health guidelines on animal use and care.
All protocols were reviewed and approved by the University of Michigan
Committee on Use and Care of Animals.
Statistical analyses. All values were expressed as the
mean ± SEM. Optical density data were expressed as percentage of
the appropriate control group for CRHex and
AVPin probes; however, because CRH hnRNA signal was very
small in the PVN of animals without NE injection, these data are
presented as raw integrated optical density units. Time course curves
were evaluated by ANOVA, followed by Sheffé's F test.
p < 0.05 was accepted as statistically significant.
 |
RESULTS |
Changes in plasma ACTH and AVP levels after NE
microinjection into the PVN
The plasma ACTH levels were 26.5 ± 4.2 pg/ml
(n = 6) at 8 A.M. in animals without NE injection.
After NE microinjection into the left PVN, plasma ACTH increased
rapidly and markedly, reached a peak at 15 min (463.4 ± 137.5 pg/ml, n = 5), then gradually returned to the basal
level by 120 min (Fig. 3A).
Plasma ACTH did not increase in the CSF-injected animals at 30 min
(Fig. 3A).

View larger version (12K):
[in this window]
[in a new window]
|
Figure 3.
Changes in plasma ACTH and AVP levels after NE
microinjection into the PVN of conscious rats. ACTH increased rapidly
and markedly after NE injection and subsided gradually by 120 min
(A). ACTH was not altered from the basal level 30 min after CSF injection into the PVN. Plasma AVP levels were not
significantly different from the basal value at any time after NE
microinjection (B). n = 5. a, p < 0.01 (vs time = 0);
b, p < 0.05 (vs CSF).
|
|
The basal plasma AVP levels were 3.6 ± 4.2 pg/ml
(n = 6). After NE injection into the PVN, plasma AVP
increased slightly at 15 min, then decreased, but it did not change
significantly from the basal level at any time throughout the
experiment (Fig. 3B).
Changes in CRH hnRNA and CRH mRNA levels in the PVN after NE
microinjection into the PVN
Representative autoradiographs of CRH hnRNA before and
after NE microinjection into the PVN are shown in Figure
4A. Expression of CRH hnRNA
was scant in the control animal in the resting state (8 A.M.) without
NE injection (Fig. 4A). CRH hnRNA increased markedly 15 min
after NE injection. Increases in CRH hnRNA were observed not only on
the NE-injected side but also on the contralateral side (Fig.
4A). Increases in CRH hnRNA lasted longer on the NE-injected side (Fig. 4A).

View larger version (60K):
[in this window]
[in a new window]
|
Figure 4.
Changes in CRH hnRNA levels in the PVN after NE
microinjection into the PVN of conscious rats. Rats were killed at
intervals after NE injection into the left PVN. CRH hnRNA was detected
by in situ hybridization using an intronic riboprobe.
Representative autoradiographs are shown in A. The
NE-injected side is indicated by *. Scale bar, 1.0 mm. Signal intensity
of each side of the PVN was quantitated separately from 10 sections per
animal (B). CRH hnRNA levels increased rapidly
and markedly on both sides of the PVN after NE injection and returned
to the basal level by 90 min. n = 5. a, p < 0.01 (vs time = 0);
b, p < 0.05 (vs time = 0);
c, p < 0.01 (vs
CSF(L)); d, p < 0.01 (vs NE(R)); e, p < 0.01 (vs CSF(R)). NE(L), NE-injected
animals, left PVN (NE-injected side); NE(R), NE-injected
animals, right PVN (contralateral side); CSF(L),
CSF-injected animals, left PVN (CSF-injected side);
CSF(R), CSF-injected animals, right PVN (contralateral
side).
|
|
Quantitative data of the autoradiographs of CRH hnRNA are shown in
Figure 4B. CRH hnRNA reached a peak at 15 min on both sides of the PVN. There was no significant difference in the peak value of
CRH hnRNA between the NE-injected and the contralateral side (approximately 70 times as high as the basal level on both sides). CRH
hnRNA returned to the baseline by 90 min on the NE-injected side and by
60 min on the contralateral side, respectively. CRH hnRNA level was
significantly higher on the NE-injected side at 30 and 60 min compared
with the contralateral side (Fig. 4B). Thus, the increase in
CRH hnRNA lasted longer on the NE-injected side as was observed in
autoradiographs in Figure 4A. No increase was observed in
the CSF-injected animals at 30 min (Fig. 4B).
Quantitative analysis of CRH mRNA is shown in Figure
5. CRH mRNA levels increased slightly but
significantly on both sides of the PVN (~30% compared with the basal
levels) at 90 min after NE injection.

View larger version (15K):
[in this window]
[in a new window]
|
Figure 5.
Changes in CRH mRNA levels in the PVN after NE
microinjection into the PVN of conscious rats. CRH mRNA levels
increased slightly but significantly at 90 min on both sides of the PVN
compared with the basal value. n = 5. a, p < 0.05 (vs time = 0). For
abbreviations see legend to Figure 4.
|
|
Changes in AVP hnRNA Levels in the PVN after NE
microinjection into the PVN
In contrast to CRH hnRNA, AVP hnRNA was clearly observed
before NE injection at 8 A.M., especially in the magnocellular division of the PVN (Fig. 6A). No clear
increase in AVP hnRNA was observed after NE injection (Fig.
6A). When these data were quantitated, AVP hnRNA did not
change significantly after NE injection (Fig. 6B).

View larger version (63K):
[in this window]
[in a new window]
|
Figure 6.
Changes in AVP hnRNA levels in the PVN after NE
microinjection into the PVN. In situ hybridization was
performed using a riboprobe corresponding to AVP intron 1. A, Representative autoradiographs. *, injected side.
Scale bar, 1.0 mm. B, Quantitative analysis. AVP hnRNA
did not change significantly after NE injection. n = 5. For abbreviations see legend to Figure 4.
|
|
Because the AVP hnRNA expression in the magnocellular division is much
more prominent than that in the parvocellular division, the
magnocellular component may mask any change in the parvocellular division if they are quantitated altogether as described above. To
further examine AVP hnRNA changes in the parvocellular division, these
sections were emulsion-dipped, and dark-field photomicrographs were
taken. As shown in Figure 7A,
no clear change in AVP hnRNA was observed in the parvocellular division
of the PVN after NE injection.

View larger version (56K):
[in this window]
[in a new window]
|
Figure 7.
Changes in AVP hnRNA levels in the parvocellular
division of the PVN after NE microinjection into the PVN. Dark-field
photomicrographs were taken using emulsion-dipped sections.
A, Representative photomicrographs. *, injected side.
Scale bar, 0.5 mm. B, AVP hnRNA in the parvocellular
division was quantitated using the method in Figure 2. AVP hnRNA in the
parvocellular division did not change significantly after NE injection.
n = 5. For abbreviations see legend to Figure
4.
|
|
On each side of the PVN, optical density of AVP hnRNA in the
parvocellular division was quantitated by circumscribing the CRH
mRNA-positive area on an AVP hnRNA photomicrograph (Fig. 2; see
Materials and Methods). Although a slight increase in AVP hnRNA was
observed on both sides of the PVN at 120 min, this was not
statistically significant (Fig. 7B).
 |
DISCUSSION |
The present results showed clearly that a
neurotransmitter, NE, regulates CRH and AVP gene transcription
differentially, indicating the complexity of genomic regulation of
multiple peptides that are co-produced in discrete neurons and bear a
common physiological role as hypophysiotropic hormones.
CRH and AVP are colocalized in a population of the parvocellular
neurons (Tramu et al., 1983 ; Mouri et al., 1993 ), and expression of
these two peptides is regulated in a parallel manner under certain
experimental conditions. For example, bilateral adrenalectomy increased
the immunoreactivity of both CRH and AVP in the parvocellular PVN, and
dexamethasone supplementation prevented the adrenalectomy-induced upregulation (Itoi et al., 1987 ). In the present experimental paradigm,
however, NE did not increase the AVP hnRNA level in the parvocellular
PVN, which is in contrast to the marked increase in the CRH hnRNA
level. These results indicate that this neurotransmitter differentially
regulates CRH and AVP gene transcription in the parvocellular neurons.
A substantial amount of CRH was presumably secreted into the portal
vessels in this experimental condition, because proopiomelanocortin
mRNA increased in the anterior pituitary after NE injection into the
PVN in the previous study (Itoi et al., 1994 ), which used an identical
experimental paradigm. It is not clear, however, whether NE application
stimulated co-secretion of AVP into the pituitary portal circulation.
Kovacs and Sawchenko (1996) reported recently that CRH hnRNA increased
very rapidly and reached a peak 5 min after ether inhalation, but AVP
hnRNA in the parvocellular division increased later and reached a peak
at 120 min. In the present study, AVP hnRNA increased slightly at 120 min in the parvocellular division, but that increase was not
statistically significant. In addition, the magnitude of CRH hnRNA
increase was much more prominent in our experiment compared with the
Kovacs and Sawchenko study (1996 ). This discrepancy raises the
possibility that the ether-induced activation of the CRH neurons may be
mediated by additional neurotransmitter(s) or neurotransmitter(s) other
than NE that may stimulate both CRH and AVP gene transcription.
Previous work has shown that NE, microinjected into the PVN of
conscious rats, stimulated CRH mRNA expression by Northern blot
analysis (Itoi et al., 1994 ). The amount of cytoplasmic CRH mRNA,
however, is determined by the balance of the rate of mRNA synthesis and
its turnover, so the increased mRNA level does not necessarily imply an
increase in CRH gene transcription. Adler et al. (1992) reported an
example of increased CRH mRNA without transcriptional activation. A
phorbol ester, 12-O-tetradecanoyl phorbol 13-acetate (TPA),
increased CRH mRNA poly(A+) tail length in the human
hepatoma cell line NPLC, which may influence CRH mRNA stability
or translatability. Our present results demonstrate that NE stimulates
CRH gene expression at the transcriptional level by showing a rapid and
marked increase in CRH hnRNA after NE microinjection into the PVN.
Unilateral microinjection unexpectedly elicited not only the
ipsilateral but also the contralateral activation. Activation of one
side of the PVN might have activated the contralateral side through the
neural pathways connecting both nuclei. We cannot rule out the
possibility of diffusion of a small portion of the injected NE to the
contralateral side. Judging from the extent of diffusion of tritiated
NE injection (Fig. 1), however, this seems less probable.
Characteristically, the NE-induced increase in CRH hnRNA was
short-lasting, and a large proportion of the increment subsided within
1 hr. By contrast, CRH mRNA increased later at 90 min, suggesting that
it took the primary transcript this length of time to be spliced into
mature mRNA. It is not clear whether the rapid "turn off" of the
transcriptional activation is caused by the negative-feedback effect by
increased plasma corticosterone or whether other mechanisms participate
in terminating the acute effect of NE. The AVP gene in the
parvocellular division seems more sensitive to glucocorticoid feedback
than the CRH gene (Ma et al., 1997 ), and the NE-induced activation of
the intracellular signaling pathway may not be able to turn on AVP gene
transcription in the presence of increased circulating glucocorticoid
levels caused by the NE injection.
The functional significance of the cyclic AMP (cAMP)-dependent
protein kinase A (PKA) pathway and the cAMP response element-binding protein (CREB) is fairly well established in both rat fetal primary culture (Emanuel et al., 1990 ) and transfected tumor cells (Seasholtz et al., 1988 ; Dorin et al., 1989 ; Spengler et al., 1992 ; Guardiola-Diaz et al., 1994 ). The cAMP response element (CRE) consensus sequence, 5'-flanking the CRH gene, has been demonstrated to bind the CREB, which
is essential to the transcriptional activation of the gene. A recent
report showed that 8-bromo-cAMP stimulated hypothalamic CRH mRNA
expression after direct injection into the PVN in vivo (Itoi
et al., 1996 ). Furthermore, pretreatment with antisense oligodeoxyribonucleotide against CREB inhibited the stress-induced CRH
mRNA expression (Itoi et al., 1996 ). These results strongly suggest the
physiological relevance of the PKA pathway in mediating the
stress-induced activation of the CRH gene.
The rapid increase in CRH hnRNA after NE injection in the present study
also favors the notion that the PKA pathway is involved in the
intracellular signaling, because phosphorylation of CREB takes place
quite rapidly without protein synthesis (Kovacs and Sawchenko, 1996 ).
Although an increase in c-fos mRNA was reported in the PVN
after insulin-induced hypoglycemia (Itoi et al., 1996 ) or metyrapone
administration (Herman et al., 1992 ), the increase was not rapid
enough to explain the participation of Fos protein in CRH gene
transcription. The rapid peak of CRH hnRNA (15 min after NE
injection) in the present study could not be explained by the newly
synthesized Fos protein either.
Many lines of evidence support the view that the
1-adrenergic receptors mediate catecholaminergic
transmission to hypothalamic CRH neurons (Plotsky, 1987b ; Kiss and
Aguilera, 1992 ; Whitnall et al., 1993 ; Itoi et al., 1994 ). Postsynaptic
1-receptors, most likely mediating the present
NE-elicited effects (Itoi et al., 1994 ), are known to be coupled to the
Gq/11 class of G-protein that activates phospholipase C to
produce diacylglycerol and inositol triphosphate (Sekar and Roufogalis,
1984 ), the former leading to the activation of the protein kinase C
(PKC) pathway and the latter prompting mobilization of intracellular
calcium (Nishizuka, 1984 ). Increases in intracellular calcium can
stimulate CREB phosphorylation, possibly through the activation of the
calcium-calmodulin-dependent protein kinase (Sheng et al., 1991 ). Thus
CREB may participate in CRH gene transcription without the involvement
of cAMP or PKA. The involvement of a diacylglycerol-dependent PKC
pathway cannot be ruled out, however, because it may possibly
contribute partly to a slower mechanism of CRH gene transcription. We
observed recently that TPA stimulates CRH gene expression in the human
neuroblastoma cell line BE(2)-M17, which has an intrinsic ability to
produce CRH peptide (K. Itoi and A. Seasholtz, unpublished observation).
AVP hnRNA was clearly observed in the resting state, before NE
injection, especially in the magnocellular divisions of the PVN as well
as the SON, indicating a constant basal transcription of the AVP gene.
This makes a striking contrast to the very low basal CRH hnRNA level.
Because the magnocellular component of AVP hnRNA was much more
prominent than the parvocellular component, AVP hnRNA levels determined
by autoradiographic images on x-ray films could be interpreted as
mostly representing the magnocellular component. (To keep the
magnocellular intensity within the detection limit of the image
analysis system, the exposure time for AVP hnRNA was kept short.) The
present result indicates that acute NE application does not stimulate
the AVP gene transcription in the magnocellular PVN. Although a slight
increase in plasma AVP concentration was observed after NE injection
into the PVN, the increase was not statistically significant in the
present study. Willoughby et al. (1987) reported that microinjection of
NE into bilateral SON elicited a rapid and marked plasma AVP increase in unanesthetized rats. Because the dose of NE used in the experiment was comparable to that in the present study, the response of
vasopressinergic neurons to NE may be different in the SON and PVN. It
needs to be kept in mind that the responsiveness of the
vasopressinergic neurons to NE may be modified by other neuromodulators
such as neuropeptide Y, galanin, and substance P, which are contained in the A1-noradrenergic neurons (Cunningham and Sawchenko,
1991 ).
The intracellular signaling mechanism of the AVP neurons, as well as
the transcriptional regulation of the AVP gene, is ill understood.
Although the cAMP-mediated AVP gene expression has been demonstrated,
and the promoter region, 5' flanking the AVP gene, contains AP-2 and
CRE sites (Pardy et al., 1992 ; Iwasaki et al., 1997 ), the functionality
of these sites in mediating transcriptional activation is not as clear
as the CRE site upstream of the CRH gene (Iwasaki et al., 1997 ).
Further studies are necessary to explore the intracellular and
molecular mechanisms underlying the differential regulation of CRH and
AVP gene transcription by NE.
 |
FOOTNOTES |
Received Nov. 24, 1998; revised March 8, 1999; accepted April 9, 1999.
This study was supported by a grant from National Institute of Mental
Health Program Project MH42251 (S.J.W.) and a grant from the Ministry
of Education, Science, Sports, and Culture of Japan 08044232 (K.I.). We
acknowledge the expert advice of Dr. Huda Akil and Dr. Audrey F. Seasholtz and the technical assistance of Sharon Burke and James Stewart.
Correspondence should be addressed to Dr. Keiichi Itoi, The Second
Department of Internal Medicine, Tohoku University School of Medicine,
Sendai 980-8574, Japan.
 |
REFERENCES |
-
Adler GK,
Rosen LB,
Fiandaca MJ,
Majzoub JA
(1992)
Protein kinase-C activation increases the quantity and poly(A) tail length of corticotropin-releasing hormone messenger RNA in NPLC cells.
Mol Endocrinol
6:476-484[Abstract/Free Full Text].
-
Bloom FE,
Battenberg ELF,
Rivier J,
Vale W
(1982)
Corticotropin-releasing factor (CRF): immunoreactive neurons and fibers in rat hypothalamus.
Regul Pept
4:43-48[Web of Science][Medline].
-
Bruhn TO,
Sutton RE,
Rivier CL,
Vale WW
(1984)
Corticotropin-releasing factor regulates proopiomelanocortin messenger ribonucleic acid levels in vivo.
Neuroendocrinology
39:170-175[Web of Science][Medline].
-
Cunningham Jr ET,
Sawchenko PE
(1988)
Anatomical specificity of noradrenergic inputs to the paraventricular and supraoptic nuclei of the rat hypothalamus.
J Comp Neurol
274:60-76[Web of Science][Medline].
-
Cunningham Jr ET,
Sawchenko PE
(1991)
Reflex control of magnocellular vasopressin and oxytocin secretion.
Trends Neurosci
14:406-411[Web of Science][Medline].
-
Dierickx K
(1980)
Immunocytochemical localization of the vertebrate cyclic nonapeptide neurohypophyseal hormones and neurophysins.
Int Rev Cytol
62:119-185[Medline].
-
Dorin RI,
Takahashi H,
Nakai Y,
Fukata J,
Naitoh Y,
Imura H
(1989)
Regulation of human corticotropin-releasing hormone gene expression by 3',5'-cyclic adenosine monophosphate in a transfected mouse corticotroph cell line.
Mol Endocrinol
3:1537-1544[Abstract/Free Full Text].
-
Emanuel RL,
Girard DM,
Thull DL,
Majzoub JA
(1990)
Second messengers involved in the regulation of corticotropin-releasing hormone mRNA and peptide in cultured rat fetal hypothalamic primary cultures.
Endocrinology
126:3016-3021[Abstract/Free Full Text].
-
Gillies GE,
Linton EA,
Lowry PJ
(1982)
Corticotropin-releasing activity of the new CRF is potentiated several times by vasopressin.
Nature
299:355-357[Medline].
-
Guardiola-Diaz HM,
Boswell C,
Seasholtz AF
(1994)
The cAMP-responsive element in the corticotropin-releasing hormone gene mediates transcriptional regulation by depolarization.
J Biol Chem
269:14784-14791[Abstract/Free Full Text].
-
Herman JP,
Schafer MK-H,
Thompson RC,
Watson SJ
(1992)
Rapid regulation of corticotropin-releasing hormone gene transcription in vivo.
Mol Endocrinol
6:1061-1069[Abstract/Free Full Text].
-
Itoi K,
Mouri T,
Takahashi K,
Murakami O,
Imai Y,
Sasaki S,
Yoshinaga K,
Sasano N
(1987)
Suppression by glucocorticoid of the immunoreactivity of corticotropin-releasing factor and vasopressin in the paraventricular nucleus of rat hypothalamus.
Neurosci Lett
73:231-236[Web of Science][Medline].
-
Itoi K,
Suda T,
Tozawa F,
Dobashi I,
Ohmori N,
Sakai Y,
Abe K,
Demura H
(1994)
Microinjection of norepinephrine into the paraventricular nucleus of the hypothalamus stimulates corticotropin-releasing factor gene expression in conscious rats.
Endocrinology
135:2177-2182[Abstract].
-
Itoi K,
Horiba N,
Tozawa F,
Sakai Y,
Sakai K,
Abe K,
Demura H,
Suda T
(1996)
Major role of 3',5'-cyclic adenosine monophosphate-dependent protein kinase A pathway in corticotropin-releasing factor gene expression in the rat hypothalamus.
Endocrinology
137:2389-2396[Abstract].
-
Itoi K,
Seasholtz AF,
Watson SJ
(1998)
Cellular and extracellular regulatory mechanisms of hypothalamic corticotropin-releasing hormone neurons.
Endocr J
45:13-33[Web of Science][Medline].
-
Iwasaki Y,
Oiso Y,
Saito H,
Majzoub JA
(1997)
Positive and negative regulation of the rat vasopressin gene promoter.
Endocrinology
138:5266-5274[Abstract/Free Full Text].
-
Kiss A,
Aguilera G
(1992)
Participation of
1-adrenergic receptors in the secretion of hypothalamic corticotropin-releasing hormone during stress.
Neuroendocrinology
56:153-160[Web of Science][Medline]. -
Kovacs KJ,
Sawchenko PE
(1996)
Sequence of stress-induced alterations in indices of synaptic and transcriptional activation in parvocellular neurosecretory neurons.
J Neurosci
16:262-273[Abstract/Free Full Text].
-
Liposits Z,
Phelix C,
Paull WK
(1986)
Electron microscopic analysis of tyrosine hydroxylase, dopamine-
-hydroxylase and phenylethanolamine-N-methyltransferase immunoreactive innervation of the hypothalamic paraventricular nucleus in the rat.
Histochemistry
84:105-120[Web of Science][Medline]. -
Ma X-M,
Levy A,
Lightman SL
(1997)
Rapid changes of heteronuclear RNA for arginine vasopressin but not for corticotropin-releasing hormone in response to acute corticosterone administration.
J Neuroendocrinol
9:723-728[Web of Science][Medline].
-
Merchenthaler I,
Vigh S,
Petrusz P,
Schally AV
(1982)
Immunocytochemical localization of corticotropin-releasing factor (CRF) in the rat brain.
Am J Anat
165:385-396[Web of Science][Medline].
-
Mouri T,
Itoi K,
Takahashi K,
Suda T,
Murakami O,
Yoshinaga K,
Andoh N,
Ohtani H,
Masuda T,
Sasano N
(1993)
Colocalization of corticotropin-releasing factor and vasopressin in the paraventricular nucleus of the human hypothalamus.
Neuroendocrinology
57:34-39[Web of Science][Medline].
-
Nishizuka Y
(1984)
The role of protein kinase C in cell surface signal transduction and tumour promotion.
Nature
308:693-698[Medline].
-
Olschowka JA,
O'Donohue TL,
Mueller GP,
Jacobowitz DM
(1982)
Hypothalamic and extrahypothalamic distribution of CRF-like immunoreactive neurons in the rat brain.
Neuroendocrinology
35:305-308[Web of Science][Medline].
-
Pardy K,
Adan RAH,
Carter DA,
Seah V,
Burbach JPH,
Murphy D
(1992)
The identification of a cis-acting element involved in cyclic 3',5'-adenosine monophosphate regulation of bovine vasopressin gene expression.
J Biol Chem
267:21746-21752[Abstract/Free Full Text].
-
Plotsky PM
(1987a)
Regulation of hypophysiotrophic factors mediating ACTH secretion.
Ann NY Acad Sci
512:205-217[Medline].
-
Plotsky PM
(1987b)
Facilitation of immunoreactive corticotropin-releasing factor secretion into the hypophysial-portal circulation after activation of catecholaminergic pathways or central norepinephrine injection.
Endocrinology
121:924-930[Abstract/Free Full Text].
-
Plotsky PM,
Cunningham Jr ET,
Widmaier EP
(1989)
Catecholaminergic modulation of corticotropin-releasing factor and adrenocorticotropin secretion.
Endocr Rev
10:437-458[Abstract/Free Full Text].
-
Renaud LP,
Bourque CW
(1991)
Neurophysiology and neuropharmacology of hypothalamic magnocellular neurons secreting vasopressin and oxytocin.
Prog Neurobiol
36:131-169[Web of Science][Medline].
-
Robertson CL
(1977)
The regulation of vasopressin function in health and disease.
Recent Prog Horm Res
33:333-385.
-
Sawchenko PE,
Swanson LW
(1981)
Central noradrenergic pathways for the integration of hypothalamic neuroendocrine and autonomic responses.
Science
214:685-687[Abstract/Free Full Text].
-
Seasholtz AF,
Thompson RC,
Douglass JO
(1988)
Identification of a cyclic adenosine monophosphate-responsive element in the rat corticotropin-releasing hormone gene.
Mol Endocrinol
2:1311-1319[Abstract/Free Full Text].
-
Sekar MC,
Roufogalis BD
(1984)
Comparison of muscarinic and
-adrenergic receptors in rat atria based on phosphoinositide turnover.
Life Sci
35:1527-1533[Web of Science][Medline]. -
Sheng M,
Thompson MA,
Greenberg ME
(1991)
CREB: a Ca2+-regulated transcription factor phosphorylated by calmodulin-dependent kinases.
Science
252:1427-1430[Abstract/Free Full Text].
-
Skorecki KL,
Brown D,
Ercolani L,
Ausiello DA
(1992)
Molecular mechanisms of vasopressin action in the kidney.
In: Handbook of physiology, Section 8, Vol 2 (Windhager EE,
ed), pp 1185-1218. New York: Oxford UP.
-
Spengler D,
Rupprecht R,
Van LP,
Holsboer F
(1992)
Identification and characterization of a 3',5'-cyclic adenosine monophosphate-responsive element in the human corticotropin-releasing hormone gene promoter.
Mol Endocrinol
6:1931-1941[Abstract/Free Full Text].
-
Tramu G,
Croix C,
Pillez A
(1983)
Ability of the CRF immunoreactive neurons of the paraventricular nucleus to produce a vasopressin-like material.
Neuroendocrinology
37:467-469[Web of Science][Medline].
-
Vale W,
Spiess J,
Rivier C,
Rivier J
(1981)
Characterization of a 41-residue ovine hypothalamic peptide that stimulates secretion of corticotropin and beta-endorphin.
Science
213:1394-1397[Free Full Text].
-
Whitnall MH,
Mezey E,
Gainer H
(1985)
Co-localization of corticotropin-releasing factor and vasopressin in median eminence neurosecretory vesicles.
Nature
317:248-250[Medline].
-
Whitnall MH,
Kiss A,
Aguilera G
(1993)
Contrasting effects of central alpha-1-adrenoreceptor activation on stress-responsive and stress-nonresponsive subpopulations of corticotropin-releasing hormone neurosecretory cells in the rat.
Neuroendocrinology
58:42-48[Web of Science][Medline].
-
Willoughby JO,
Jervois PM,
Menadue MF,
Blessing WW
(1987)
Noradrenaline, by activation of alpha-1-adrenoceptors in the region of the supraoptic nucleus, causes secretion of vasopressin in the unanaesthetized rat.
Neuroendocrinology
45:219-222[Web of Science][Medline].
Copyright © 1999 Society for Neuroscience 0270-6474/99/19135464-09$05.00/0
This article has been cited by other articles:

|
 |

|
 |
 
R. Kvetnansky, E. L. Sabban, and M. Palkovits
Catecholaminergic Systems in Stress: Structural and Molecular Genetic Approaches
Physiol Rev,
April 1, 2009;
89(2):
535 - 606.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. van der Laan, S. B. Lachize, E. Vreugdenhil, E. R. de Kloet, and O. C. Meijer
Nuclear Receptor Coregulators Differentially Modulate Induction and Glucocorticoid Receptor-Mediated Repression of the Corticotropin-Releasing Hormone Gene
Endocrinology,
February 1, 2008;
149(2):
725 - 732.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. M. Khan, T. A. Ponzio, G. Sanchez-Watts, B. G. Stanley, G. I. Hatton, and A. G. Watts
Catecholaminergic Control of Mitogen-Activated Protein Kinase Signaling in Paraventricular Neuroendocrine Neurons In Vivo and In Vitro: A Proposed Role during Glycemic Challenges
J. Neurosci.,
July 4, 2007;
27(27):
7344 - 7360.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. A. Clark, S. M. J. MohanKumar, B. S. Kasturi, and P. S. MohanKumar
Effects of central and systemic administration of leptin on neurotransmitter concentrations in specific areas of the hypothalamus
Am J Physiol Regulatory Integrative Comp Physiol,
February 1, 2006;
290(2):
R306 - R312.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
G. Wittmann, Z. Liposits, R. M. Lechan, and C. Fekete
Origin of Cocaine- and Amphetamine-Regulated Transcript-Containing Axons Innervating Hypophysiotropic Corticotropin-Releasing Hormone-Synthesizing Neurons in the Rat
Endocrinology,
July 1, 2005;
146(7):
2985 - 2991.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Ritter, A. G. Watts, T. T. Dinh, G. Sanchez-Watts, and C. Pedrow
Immunotoxin Lesion of Hypothalamically Projecting Norepinephrine and Epinephrine Neurons Differentially Affects Circadian and Stressor-Stimulated Corticosterone Secretion
Endocrinology,
April 1, 2003;
144(4):
1357 - 1367.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C.-M. Vacher, P. Fretier, C. Creminon, A. Calas, and H. Hardin-Pouzet
Activation by Serotonin and Noradrenaline of Vasopressin and Oxytocin Expression in the Mouse Paraventricular and Supraoptic Nuclei
J. Neurosci.,
March 1, 2002;
22(5):
1513 - 1522.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. L. Cole and P. E. Sawchenko
Neurotransmitter Regulation of Cellular Activation and Neuropeptide Gene Expression in the Paraventricular Nucleus of the Hypothalamus
J. Neurosci.,
February 1, 2002;
22(3):
959 - 969.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. E. Kresse, M. Million, E. Saperas, and Y. Tache
Colitis induces CRF expression in hypothalamic magnocellular neurons and blunts CRF gene response to stress in rats
Am J Physiol Gastrointest Liver Physiol,
November 1, 2001;
281(5):
G1203 - G1213.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. P. Mendoza and J. D. Ruys
The beginning of an alternative view of the neurobiology of emotion
Social Science Information,
March 1, 2001;
40(1):
39 - 60.
[Abstract]
[PDF]
|
 |
|
|